Results 21 to 30 of about 1,238,265 (360)

Effect of Small-molecule Inhibitor CIL56 on Death of Esophageal Squamous Cell Carcinoma Cells

open access: yesZhongliu Fangzhi Yanjiu, 2023
Objective To investigate the role and mechanism of the small-molecule inhibitor CIL56 in the death of esophageal squamous cell carcinoma cells. Methods SRB method and plate-cloning method were used to detect the effect of CIL56 on the proliferation of ...
CHEN Jiaxing, XU Xiaqing, ZHANG Qi
doaj   +1 more source

Primary Squamous Cell Carcinoma of Submandibular Salivary Gland with Sialo-Cutaneous Fistula: A Rare Case Report [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2015
Malignant tumours of the submandibular salivary glands are rare entities. Most common malignant tumour of submandibular gland is mucoepidermoid carcinoma.
Aditya Atul Kulkarni, Sanjiv S. Thakur
doaj   +1 more source

Squamous Cell Carcinoma [PDF]

open access: yesJAMA Dermatology, 2013
Irregular aggregates of neoplastic keratinocytes arising from the epidermis and invading the dermis.
Jeremy, Davis, Jeremy, Bordeaux
openaire   +2 more sources

Histopathological Assessment for Esophageal Squamous Cell Carcinoma [PDF]

open access: yes, 2020
Histological assessment of esophageal squamous malignancies is crucial for management of patients with the cancer as well as working in research on the cancer.
Lam, AK, Alfred K. Lam
core   +1 more source

Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas

open access: yesHeliyon, 2023
Inflammation, especially chronic inflammation, is closely linked to tumor development. As essential chronic inflammatory cytokines, the interleukin family plays a key role in inflammatory infections and malignancies.
Yujie Ding   +3 more
doaj   +1 more source

p40 Immunohistochemistry Is an Excellent Marker in Primary Lung Squamous Cell Carcinoma [PDF]

open access: yesJournal of Pathology and Translational Medicine, 2018
Background Lung cancer is the third most common cancer worldwide. With major advances in the molecular testing of lung cancers and the introduction of targeted therapies, the distinction between adenocarcinoma and squamous cell carcinoma as well as ...
Khairunisa Ahmad Affandi   +3 more
doaj   +1 more source

Primary squamous cell carcinoma of the liver: a case report

open access: yesJournal of International Medical Research, 2021
Primary squamous cell carcinoma of the liver is extremely rare, very difficult to diagnose, and carries an extremely poor prognosis. In this study, we discuss the imaging features of a patient with primary hepatic squamous cell carcinoma. The patient was
Yu Sun, Guangyu Jin
doaj   +1 more source

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated ...
Hui‐yan Luo   +29 more
semanticscholar   +1 more source

Squamous cell carcinoma of the eyelid

open access: yesJapanese Journal of Clinical Oncology, 2023
Abstract Eyelid squamous cell carcinoma is a major type of rare eyelid cancer, together with basal cell carcinoma and sebaceous gland carcinoma. It is a painless disease that progresses slowly and is often detected by the appearance of nodules or plaques.
Yasuyoshi Sato   +5 more
openaire   +2 more sources

Cutaneous HPV16 and p16 Positive Basaloid Squamous Cell Carcinoma with Brain Metastasis: A Case Report

open access: yesSAGE Open Medical Case Reports, 2020
Basaloid squamous cell carcinoma is an infiltrative and aggressive variant of squamous cell carcinoma with basaloid features. Primary skin-derived basaloid squamous cell carcinoma is rare.
Trang T Vu   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy